Cover Image
市場調查報告書

Ecrins Therapeutics SAS的產品平台分析

Ecrins Therapeutics SAS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319972
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Ecrins Therapeutics SAS的產品平台分析 Ecrins Therapeutics SAS - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 24 Pages
簡介

Ecrins Therapeutics SAS是總公司在法國有的生物科技企業,進行低分子醫藥品的藥物研發及開發。產品有管磷和管磷聚合反應檢測套件、單株抗體等。成長阻礙、細胞骨骼染色、血管新生等的化驗相關資料,提供in vivo 及in vitro的化驗服務。

本報告提供Ecrins Therapeutics SAS的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Ecrins Therapeutics SAS的基本資料

  • Ecrins Therapeutics SAS概要
  • 主要資訊
  • 企業資料

Ecrins Therapeutics SAS:R&D概要

  • 主要的治療範圍

Ecrins Therapeutics SAS:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Ecrins Therapeutics SAS:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Ecrins Therapeutics SAS:藥物簡介

  • ETD-5
  • ET-025
  • ET-058
  • ET-088
  • ET-098
  • ET-099
  • ET-100

Ecrins Therapeutics SAS:開發平台分析

  • 各給藥途徑
  • 各分子類型

Ecrins Therapeutics SAS:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06970CDB

Summary

Global Markets Direct's, 'Ecrins Therapeutics SAS - Product Pipeline Review - 2015', provides an overview of the Ecrins Therapeutics SAS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ecrins Therapeutics SAS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ecrins Therapeutics SAS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ecrins Therapeutics SAS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ecrins Therapeutics SAS's pipeline products

Reasons to buy

  • Evaluate Ecrins Therapeutics SAS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ecrins Therapeutics SAS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ecrins Therapeutics SAS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ecrins Therapeutics SAS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ecrins Therapeutics SAS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ecrins Therapeutics SAS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ecrins Therapeutics SAS Snapshot
    • Ecrins Therapeutics SAS Overview
    • Key Information
    • Key Facts
  • Ecrins Therapeutics SAS - Research and Development Overview
    • Key Therapeutic Areas
  • Ecrins Therapeutics SAS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ecrins Therapeutics SAS - Pipeline Products Glance
    • Ecrins Therapeutics SAS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Ecrins Therapeutics SAS - Drug Profiles
    • ETD-5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-025
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-058
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-088
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-098
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-099
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ecrins Therapeutics SAS - Pipeline Analysis
  • Ecrins Therapeutics SAS - Pipeline Products by Target
  • Ecrins Therapeutics SAS - Pipeline Products by Route of Administration
  • Ecrins Therapeutics SAS - Pipeline Products by Molecule Type
  • Ecrins Therapeutics SAS - Pipeline Products by Mechanism of Action
  • Ecrins Therapeutics SAS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ecrins Therapeutics SAS, Key Information
  • Ecrins Therapeutics SAS, Key Facts
  • Ecrins Therapeutics SAS - Pipeline by Indication, 2015
  • Ecrins Therapeutics SAS - Pipeline by Stage of Development, 2015
  • Ecrins Therapeutics SAS - Monotherapy Products in Pipeline, 2015
  • Ecrins Therapeutics SAS - Preclinical, 2015
  • Ecrins Therapeutics SAS - Discovery, 2015
  • Ecrins Therapeutics SAS - Pipeline by Target, 2015
  • Ecrins Therapeutics SAS - Pipeline by Route of Administration, 2015
  • Ecrins Therapeutics SAS - Pipeline by Molecule Type, 2015
  • Ecrins Therapeutics SAS - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Ecrins Therapeutics SAS - Pipeline by Top 10 Indication, 2015
  • Ecrins Therapeutics SAS - Pipeline by Stage of Development, 2015
  • Ecrins Therapeutics SAS - Monotherapy Products in Pipeline, 2015
  • Ecrins Therapeutics SAS - Pipeline by Top 10 Route of Administration, 2015
  • Ecrins Therapeutics SAS - Pipeline by Top 10 Molecule Type, 2015
Back to Top